A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis | MicrobiomeTrials← Back to trialsNCT07632976
A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-05-25Est. Completion: 2027-09-30
Enrollment target: 12 participants Locations- Peking University People's Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Antiphospholipid Syndrome (APS)
This is a phase II, single-centre, open-label pilot study evaluating the safety and tolerability of anifrolumab in adult…
Athens, GreeceEst. completion Jun 2028
Antiphospholipid Syndrome
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are prot…
Durham, United StatesEst. completion Mar 2029